{"prompt": "['individual. The study will comply with the requirements of the ICH E2A guideline (Clinical', 'Safety Data Management: Definitions and Standards for Expedited Reporting). Studies', 'conducted in the United States or under a U.S. Investigational New Drug (IND) Application', 'will comply with U.S. Food and Drug Administration regulations and applicable local, state,', 'and federal laws. Studies conducted in the EU or European Economic Area will comply with', 'the EU Clinical Trial Directive (2001/20/EC).', '8.2', 'INFORMED CONSENT', \"The Sponsor's sample Informed Consent Form will be provided to each site. If applicable, it\", 'will be provided in a certified translation of the local language. The Sponsor or its designee', \"must review and approve any proposed deviations from the Sponsor's sample Informed\", 'Consent Forms or any alternate consent forms proposed by the site (collectively, the', '\"Consent Forms\") before IRB/EC submission. The final IRB/EC-approved Consent Forms', 'must be provided to the Sponsor for health authority submission purposes according to local', 'requirements.', 'If applicable, the Informed Consent Form will contain separate sections for any optional', 'procedures. The investigator or authorized designee will explain to each patient the', 'objectives, methods, and potential risks associated with each optional procedure. Patients', 'will be told that they are free to refuse to participate and may withdraw their consent at any', \"time for any reason. A separate, specific signature will be required to document a patient's\", 'agreement to participate in optional procedures. Patients who decline to participate will not', 'provide a separate signature.', \"The Consent Forms must be signed and dated by the patient or the patient's legally\", 'authorized representative before his or her participation in the study. The case history or', 'clinical records for each patient shall document the informed consent process and that', 'written informed consent was obtained prior to participation in the study.', 'The Consent Forms should be revised whenever there are changes to study procedures or', 'when new information becomes available that may affect the willingness of the patient to', 'participate. The final revised IRB/EC-approved Consent Forms must be provided to the', 'Sponsor for health authority submission purposes.', 'Patients must be re-consented to the most current version of the Consent Forms (or to a', 'significant new information / findings addendum in accordance with applicable laws and', 'IRB/EC policy) during their participation in the study. For any updated or revised Consent', 'Forms, the case history or clinical records for each patient shall document the informed', 'consent process and that written informed consent was obtained using the updated / revised', 'Consent Forms for continued participation in the study.', \"A copy of each signed Consent Form must be provided to the patient or the patient's legally\", 'authorized representative. All signed and dated Consent Forms must remain in each', \"patient's study file or in the site file and must be available for verification by study monitors at\", 'any time.', 'For sites in the United States, each Consent Form may also include patient authorization to', 'allow use and disclosure of personal health information in compliance with the U.S. Health', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '87 / Protocol MO40628, Version 12']['Insurance Portability and Accountability Act (HIPAA) of 1996. If the site utilizes a separate', 'Authorization Form for patient authorization for use and disclosure of personal health', 'information under the HIPAA regulations, the review, approval, and other processes outlined', 'above apply except that IRB review and approval may not be required per study site policies.', '8.3', 'INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE', 'This protocol, the Informed Consent Forms, any information to be given to the patient, and', 'relevant supporting information must be submitted to the IRB/EC by the Principal', 'Investigator and reviewed and approved by the IRB/EC before the study is initiated.', 'In addition, any patient recruitment materials must be approved by the IRB/EC.', 'The Principal Investigator is responsible for providing written summaries of the status of the', 'study to the IRB/EC annually or more frequently in accordance with the requirements,', 'policies, and procedures established by the IRB/EC. Investigators are also responsible for', 'promptly informing the IRB/EC of any protocol amendments (see Section 9.6).', 'In addition to the requirements for reporting all AEs to the Sponsor, investigators must', 'comply with requirements for reporting SAEs to the local health authority and IRB/EC.', 'Investigators may receive written IND safety reports or other safety-related communications', 'from the Sponsor. Investigators are responsible for ensuring that such reports are reviewed', 'and processed in accordance with health authority requirements and the policies and', \"procedures established by their IRB/EC, and archived in the site's study file.\", '8.4', 'CONFIDENTIALITY', 'The Sponsor maintains confidentiality standards by coding each patient enrolled in the study', 'through assignment of a unique patient identification number. This means that patient', 'names are not included in data sets that are transmitted to any Sponsor location.', 'Patient medical information obtained by this study is confidential and may be disclosed to', 'third parties only as permitted by the Informed Consent Form (or separate authorization for', 'use and disclosure of personal health information) signed by the patient, unless permitted or', 'required by law.', \"Medical information may be given to a patient's personal physician or other appropriate\", \"medical personnel responsible for the patient's welfare, for treatment purposes.\", 'Data generated by this study must be available for inspection upon request by', 'representatives of national and local health authorities, Sponsor monitors, representatives,', 'and collaborators, and the IRB/EC for each study site, as appropriate.', 'Study data may be submitted to government or other health research databases or shared', 'with researchers, government agencies, companies, or other groups that are not', 'participating in this study. These data may be combined with or linked to other data and', 'used for research purposes, to advance science and public health, or for analysis,', 'development, and commercialization of products to treat and diagnose disease. In addition,', 'redacted clinical study reports and other summary reports will be provided upon request.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '88 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}